Get the Stockscreener App
0.6168
8.17%
0.0466
After Hours:
.62
0.0032
+0.52%
Curis Inc stock is traded at $0.6168, with a volume of 225.03K.
It is up +8.17% in the last 24 hours and up +15.72% over the past month.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
See More
Previous Close:
$0.5702
Open:
$0.57
24h Volume:
225.03K
Relative Volume:
0.56
Market Cap:
$24.66M
Revenue:
$9.44M
Net Income/Loss:
$-7.58M
P/E Ratio:
-0.5166
EPS:
-1.194
Net Cash Flow:
$-27.20M
1W Performance:
+9.87%
1M Performance:
+15.72%
6M Performance:
-57.75%
1Y Performance:
-71.84%
1-Day Range:
$0.57
$0.6254
1-Week Range:
$0.5502
$0.6254
52-Week Range:
$0.4902
$3.13
Curis Inc Stock (CRIS) Company Profile
Name
Curis Inc
Sector
Industry
Phone
617-503-6500
Address
128 SPRING STREET, LEXINGTON, MA
Compare CRIS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRIS
Curis Inc
|
0.6168 | 22.80M | 9.44M | -7.58M | -27.20M | -1.194 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Curis Inc Stock (CRIS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Nov-17-23 | Initiated | Truist | Buy |
| Apr-04-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-13-21 | Initiated | Raymond James | Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Jul-29-20 | Initiated | Laidlaw | Buy |
| Jul-17-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Mar-02-16 | Initiated | Sun Trust Rbsn Humphrey | Buy |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Aug-11-15 | Initiated | FBR Capital | Outperform |
| Jan-22-15 | Reiterated | Oppenheimer | Outperform |
| Jan-21-15 | Reiterated | ROTH Capital | Buy |
| May-09-14 | Reiterated | Oppenheimer | Outperform |
| Oct-02-13 | Initiated | Robert W. Baird | Outperform |
| Sep-30-13 | Initiated | Chardan Capital Markets | Buy |
| Nov-14-12 | Initiated | Stifel Nicolaus | Hold |
| Jan-31-12 | Reiterated | Brean Murray | Buy |
| Jan-31-12 | Reiterated | Summer Street Research | Buy |
| Dec-09-11 | Initiated | Oppenheimer | Outperform |
| Oct-06-11 | Initiated | Summer Street Research | Buy |
| Sep-22-11 | Initiated | MLV Capital | Buy |
| Mar-21-11 | Reiterated | Brean Murray | Buy |
| Feb-26-10 | Reiterated | Roth Capital | Buy |
| Jan-07-10 | Initiated | Roth Capital | Buy |
View All
Curis Inc Stock (CRIS) Latest News
Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026 - BioSpace
Curis Faces Nasdaq Delisting Determination, Plans Appeal Hearing - TipRanks
Curis (CRIS) faces Nasdaq delisting after 30 days under $1.00 bid - Stock Titan
CRIS SEC FilingsCuris 10-K, 10-Q, 8-K Forms - Stock Titan
Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds - Quantisnow
Nantahala (NASDAQ: CRIS) holds 4.215M shares of Curis, a 9.99% stake - Stock Titan
Curis | SCHEDULE 13G: Others - Moomoo
Curis Provides Fourth Quarter 2025 Business Update (PR Newswire) - Aktiellt
Curis Live Share Prices and Trades. CRIS.US Live Streaming Share Prices. - London South East
Curis (NASDAQ: CRIS) 2026 proxy seeks director votes and higher authorized shares - Stock Titan
Curis Inc stock (US2312691006): Is oncology pipeline strength now the key test for biotech investors - AD HOC NEWS
Curis | ARS: Annual Report to Security Holders - Moomoo
Curis (HAM:CUS0) Short-term investments - GuruFocus
Curis (CRIS) Stock: Is It a Strong Investment Case (Weakens) 2026-04-20Expert Breakout Alerts - UBND thành phố Hải Phòng
Curis Inc Stock Historical Valuations - GuruFocus
Curis Inc Stock Warning Signs | HAM:CUS0 - GuruFocus
Q3 2025 Curis Inc Earnings Call Transcript - GuruFocus
Q2 2025 Curis Inc Earnings Call Transcript - GuruFocus
Curis Inc (HAM:CUS0) Dividend - GuruFocus
Curis Inc (HAM:CUS0) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Curis Inc Stock Operating Data - GuruFocus
Curis Inc (HAM:CUS0) Valuation: Possible Value Trap, Think Twice - GuruFocus
Curis Inc (HAM:CUS0) Stock Price & 30 Year Financial Data - GuruFocus
Curis Inc (HAM:CUS0) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Curis (CRIS) Reports Q1 Loss, Tops Revenue Estimates - MSN
Is Curis (CRIS) stock under risk pressure (Investor Interest) 2026-04-18Stock Analysis Community - Cổng thông tin điện tử tỉnh Lào Cai
Curis (CRIS) upgraded to buy: What does it mean for the stock? - MSN
Curis (CRIS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Curis Inc (CRIS) Stock Price & 30 Year Financial Data - GuruFocus
Sell Signal: Whats the MACD signal for Curis Inc2026 Setups & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Form PRE 14AOther preliminary proxy statements - ADVFN
Curis (NASDAQ: CRIS) holds virtual meeting May 19; board seeks more authorized shares - Stock Titan
Curis | PRE 14A: Preliminary proxy statements relating to merger or acquisition - Moomoo
Curis targets full enrollment in PCNSL registrational study within 12–18 months while advancing CLL proof-of-concept - MSN
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX) and Curis (CRIS) - The Globe and Mail
What drove Curis (CRIS) Stock higher this week | Price at $0.55, Up 3.19%Trending Stock Ideas - Xã Vĩnh Công
Nantahala shows 4.22M stake in Curis (NASDAQ: CRIS) — 9.99% - Stock Titan
Nantahala Capital (CRIS) reports 2.94M shares, 6.98% ownership (exercisable stakes included) - Stock Titan
Is Curis (CRIS) Stock Rebounding | Price at $0.53, Down 3.07%Growth Investing - Cổng thông tin điện tử Tỉnh Sơn La
CRIS Should I Buy - Intellectia AI
Curis Inc. (CUS0.SG) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Curis, Inc. (CRIS) stock price, news, quote and history - Yahoo Finance Singapore
CRIS Stock Price, Quote & Chart | CURIS INC (NASDAQ:CRIS) - ChartMill
Curis director Kaitin buys $5487 in shares By Investing.com - Investing.com South Africa
Curis director Kaitin buys $5487 in shares - Investing.com UK
Director at Curis (NASDAQ: CRIS) makes open-market share buy - Stock Titan
Curis | 4: Statement of changes in beneficial ownership of securities-Director KAITIN KENNETH I - Moomoo
Market Review: What are analysts price targets for Curis IncQuarterly Risk Review & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Curis prices private placement of $80.8M - MSN
Aug Big Picture: Is Curis Inc exposed to political riskMarket Sentiment Summary & Weekly Top Gainers Alerts - baoquankhu1.vn
Stonepine Group (NASDAQ: CRIS) reports 4.03M shares, 9.9% stake - Stock Titan
Curis Inc Stock (CRIS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):